^
Association details:
| Biomarker: | PIK3CA mutation |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | everolimus (mTOR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Targeting mTOR and DNA repair pathways in residual triple negative breast cancer post neoadjuvant chemotherapy
Published date:
01/08/2021
Excerpt:
Twenty-four Stage II/III TNBC patients...Patients received everolimus daily orally at 10 mg for 12 weeks and cisplatin IV at 20 mg/m2 weekly for 4 cycles (21-day cycle), until definitive surgery...Patients with germline PALB2 mutation or somatic PI3KCA mutation had a pathologic response, achieving RCB-I at the surgery...
Secondary therapy:
cisplatin
DOI:
10.1038/s41598-020-80081-y
Trial ID:
